Sandostatin treatment of esophageal variceal hemorrhage observed.docVIP

 PAGE \* MERGEFORMAT 9 Sandostatin treatment of esophageal variceal hemorrhage observed [Paper Keywords] Sandostatin; vasopressin; esophageal variceal bleeding [Abstract] Objective of Sandostatin, vasopressin treatment of esophageal variceal bleeding were compared the clinical efficacy of Methods Groups of the first dose of Sandostatin Sandostatin 0.1mg + with normal saline 20mL slow intravenous injection, following the of the 25μg / h continuous infusion; vasopressin group with pituitrin to 0.2U/min amount of continuous infusion. were treated with 102 cases times the result 24h bleeding rates were 80.6% (50/62), 62.5% (25/40); average bleeding time was (5.6 + -4.1) h, (13.5 + -5.2) h. The above information were statistically significant differences. Sandostatin findings of esophageal varices treatment of bleeding, recent bleeding more precise results, significantly better than vasopressin, and the use of safe and convenient, less side effects, can be an ideal candidate as a treatment for the disease of drug. Esophagus and esophageal variceal bleeding (or) variceal bleeding is a serious complication of portal hypertension is cirrhosis of the leading causes of death. Sandostatin, vasopressin is treatment of portal hypertension associated with esophageal and gastric variceal bleeding an important drug. our department from July 2004 - December 2007 for the treatment of esophageal and two drugs (or) variceal bleeding in clinical efficacy a systematic comparative study. 1 Materials and Methods 1.1 Case Selection All patients were our department in July 2004 - December 2007 in-patients. Male 78 cases, 12 females, mean age 51 years (21 to 80 years), of which 72 cases of liver cirrhosis, alcoholic cirrhosis 7 patients, cryptogenic cirrhosis in 3 cases, hepatitis, cirrhosis and alcoholic cirrhosis in 5 patients with primary liver cancer in 3 cases. according to the patient’s financial situation and whether cardiovascular disease (such as hypertension,